Xue Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5061012/publications.pdf

Version: 2024-02-01

		361413	302126
65	1,783	20	39
papers	citations	h-index	g-index

66	66	66	2402
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2018, 24, 3097-3107.	7.0	357
2	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Antiâ€“PD-(L)1 Therapies in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 5015-5026.	7.0	143
3	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. Scientific Reports, 2017, 7, 583.	3.3	141
4	Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib inÂAdvanced NSCLC. Journal of Thoracic Oncology, 2017, 12, e65-e68.	1.1	81
5	Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics, 2019, 9, 5532-5541.	10.0	80
6	Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. Lung Cancer, 2018, 118, 1-5.	2.0	63
7	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLoS Medicine, 2021, 18, e1003741.	8.4	60
8	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clinical Lung Cancer, 2020, 21, 247-254.	2.6	48
9	Genomic signatures define three subtypes of EGFR-mutant stage IIâ€“III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications, 2021, 12, 6450.	12.8	48
10	Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. Lung Cancer, 2018, 124, 110-116.	2.0	43
11	Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. Lung Cancer, 2019, 127, 19-24.	2.0	41
12	Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Molecular Oncology, 2020, 14, 1695-1704.	4.6	41
13	EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. Journal of Thoracic Oncology, 2019, 14, 732-736.	1.1	40
14	Timing and Origins of Local and Distant Metastases in Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1136-1148.	1.1	39
15	Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. Cancer Science, 2020, 111, 2163-2173.	3.9	37
16	CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1792-1797.	1.1	29
17	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	5.9	29
18	Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinibâ€based combination therapy: A realâ€world experience of offâ€label ibrutinib use. Cancer Medicine, 2020, 9, 8676-8684.	2.8	28

#	Article	IF	Citations
19	Molecular and clinicopathological characteristics of ROS1â€rearranged nonâ€smallâ€cell lung cancers identified by nextâ€generation sequencing. Molecular Oncology, 2020, 14, 2787-2795.	4.6	25
20	Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Molecular Genetics & Genomic Medicine, 2020, 8, e1079.	1.2	23
21	<scp>NTRK</scp> fusion positive colorectal cancer is a unique subset of <scp>CRC</scp> with high <scp>TMB</scp> and microsatellite instability. Cancer Medicine, 2022, 11, 2541-2549.	2.8	22
22	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 596937.	2.8	21
23	Short-Term Responders of Nonâ€“Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms. Translational Oncology, 2018, 11, 1364-1369.	3.7	19
24	Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. BMC Cancer, 2022, 22, 550.	2.6	19
25	Heterogeneous responses and resistant mechanisms to crizotinib in ALKâ€positive advanced nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 1093-1103.	1.9	18
26	Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma. BMC Cancer, 2018, 18, 251.	2.6	18
27	Acquired multiple secondary mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a germline mutation. American Journal of Translational Research (discontinued), 2020, 12, 612-617.	0.0	18
28	Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions. Npj Precision Oncology, 2021, 5, 81.	5.4	17
29	Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases. Cancer Biology and Medicine, 2021, 18, 490-501.	3.0	16
30	Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. , 2021, 9, e002014.		16
31	Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling. Pigment Cell and Melanoma Research, 2020, 33, 601-611.	3.3	15
32	Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers. , 2021, 9, e002336.		15
33	Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients. Lung Cancer, 2020, 146, 327-334.	2.0	14
34	Quantitative characterization of tumor cell-free DNA shortening. BMC Genomics, 2020, 21, 473.	2.8	13
35	Combinatorial assessment of ctDNA release and mutational burden predicts antiâ€PD(L)1 therapy outcome in nonsmallâ€cell lung cancer. Clinical and Translational Medicine, 2020, 10, 331-336.	4.0	12
36	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. JNCI Cancer Spectrum, 2021, 5, pkaa122.	2.9	12

#	Article	IF	Citations
37	Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors. Journal of Medical Genetics, 2021, 58, 79-86.	3.2	9
38	Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets. Clinical Lung Cancer, 2022, 23, 135-142.	2.6	9
39	Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. Journal of Cancer, 2021, 12, 644-651.	2.5	8
40	Distinct genomic profile in h. pylori â€ssociated gastric cancer. Cancer Medicine, 2021, 10, 2461-2469.	2.8	8
41	Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing. Neoplasia, 2021, 23, 1204-1212.	5.3	8
42	Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1165-1176.	0.8	8
43	Comprehensive nextâ€generation profiling of clonal hematopoiesis in cancer patients using paired tumorâ€blood sequencing for guiding personalized therapies. Clinical and Translational Medicine, 2020, 10, e222.	4.0	7
44	Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling. OncoTargets and Therapy, 2021, Volume 14, 2131-2138.	2.0	7
45	Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report. BMC Cancer, 2019, 19, 592.	2.6	6
46	Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases. Journal of Translational Medicine, 2022, 20, 74.	4.4	6
47	Transformation to small cell lung cancer and activation of KRAS during longâ€term erlotinib maintenance in a patient with nonâ€small cell lung cancer: A case report. Oncology Letters, 2019, 17, 5219-5223.	1.8	5
48	Clinical and molecular characteristics of Chinese nonâ€small cell lung cancer patients with ERBB2 transmembrane domain mutations. Molecular Oncology, 2020, 14, 1731-1739.	4.6	5
49	Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients. Frontiers in Genetics, 2021, 12, 608742.	2.3	5
50	Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study. ESMO Open, 2020, 5, e000985.	4.5	4
51	Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. Frontiers in Oncology, 2020, 10, 1259.	2.8	4
52	Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response. Translational Cancer Research, 2019, 8, 2187-2191.	1.0	4
53	TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer. OncoTargets and Therapy, 2021, Volume 14, 4967-4978.	2.0	3
54	Acquired rare recurrent mutations as mechanisms of resistance to Osimertinib in lung cancer and structural modelling. American Journal of Cancer Research, 2020, 10, 4005-4015.	1.4	3

#	Article	IF	Citations
55	Somatic Alteration Characteristics of Early-Onset Gastric Cancer. Journal of Oncology, 2022, 2022, 1-11.	1.3	3
56	Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors. Cancer Communications, 2021, 41, 183-186.	9.2	2
57	Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	2.8	2
58	Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study. BMC Pulmonary Medicine, 2020, 20, 80.	2.0	1
59	Molecular diagnosis and clinical outcome of a lung cancer patient with -E285K mutated Li-Fraumeni syndrome harboring a somatic -KDD mutation. American Journal of Translational Research (discontinued), 2020, 12, 6689-6693.	0.0	1
60	Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy. OncoTargets and Therapy, 2022, Volume 15, 41-51.	2.0	1
61	Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210753.	1.3	1
62	Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. Journal of Oncology, 2022, 2022, 1-10.	1.3	1
63	Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors. Frontiers in Oncology, 2022, 12, 753311.	2.8	1
64	Clearance of circulating tumor DNA in a high-risk stage-IV rectal carcinoma patient with synchronous liver metastases after conversion surgery is correlated with pathologic complete response. Therapeutic Advances in Gastrointestinal Endoscopy, 2021, 14, 263177452110202.	1.9	0
65	Tumor infiltrating lymphocytesâ€based subtypes and genomic characteristics of <scp>EBV</scp> â€• associated lymphoepitheliomaâ€like carcinoma. Journal of Pathology, 2022, , .	4.5	0